
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+12
Syntara Limited (ASX:SNT) is a clinical stage drug development company targeting extracellular matrix dysfunction with its world-leading expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. Syntara is managing three phase 2 clinical studies in diseases of high unmet need with a further two potential phase 1c/2 studies being evaluated for 2024. Lead candidate SNT5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. SNT-5505 has already achieved FDA Orphan...
Undertreated respiratory diseases,research and development,inflammation,cancer,fibrosis,cystic fibrosis,myelofibrosis,drug discovery,fibrosis,myelofibrosis,biotechnology,drugdevelopment,clinicaltrials,biotech,bloodcancer,scarmanagement,and mds
Syntara operates in the Biotechnology industry.
Syntara's revenue is 11m - 100m
Syntara has 51 - 200 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.